vs
Side-by-side financial comparison of NOODLES & Co (NDLS) and Travere Therapeutics, Inc. (TVTX). Click either name above to swap in a different company.
Travere Therapeutics, Inc. is the larger business by last-quarter revenue ($129.7M vs $122.1M, roughly 1.1× NOODLES & Co). On growth, Travere Therapeutics, Inc. posted the faster year-over-year revenue change (73.4% vs -4.1%). Over the past eight quarters, Travere Therapeutics, Inc.'s revenue compounded faster (77.0% CAGR vs -1.2%).
Noodles & Company is an American fast-casual restaurant that offers international and American noodle dishes in addition to soups and salads. Noodles & Company was founded in 1995 by Aaron Kennedy and is headquartered in Broomfield, Colorado. The company went public in 2013 and recorded a $457 million revenue in 2017. In mid-2022, there were 458 Noodles & Company locations across 31 states.
Travere Therapeutics, Inc. is a global biopharmaceutical firm developing and commercializing innovative therapies for patients with rare, serious, life-threatening diseases. Its key segments cover rare nephrology, hepatology and metabolic disorders, serving markets across North America, Europe and other global regions.
NDLS vs TVTX — Head-to-Head
Income Statement — Q3 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $122.1M | $129.7M |
| Net Profit | $-9.2M | — |
| Gross Margin | — | 98.0% |
| Operating Margin | -5.2% | -25.0% |
| Net Margin | -7.5% | — |
| Revenue YoY | -4.1% | 73.4% |
| Net Profit YoY | 32.8% | — |
| EPS (diluted) | $-0.20 | $0.04 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $129.7M | ||
| Q3 25 | $122.1M | $164.9M | ||
| Q2 25 | $123.8M | $114.4M | ||
| Q1 25 | — | $81.7M | ||
| Q4 24 | $122.8M | $74.8M | ||
| Q3 24 | $127.4M | $62.9M | ||
| Q2 24 | $121.4M | $54.1M | ||
| Q1 24 | $124.3M | $41.4M |
| Q4 25 | — | — | ||
| Q3 25 | $-9.2M | $25.7M | ||
| Q2 25 | $-9.1M | $-12.8M | ||
| Q1 25 | — | $-41.2M | ||
| Q4 24 | $-6.8M | — | ||
| Q3 24 | $-13.6M | $-54.8M | ||
| Q2 24 | $-6.1M | $-70.4M | ||
| Q1 24 | $-6.1M | $-136.1M |
| Q4 25 | — | 98.0% | ||
| Q3 25 | — | 99.0% | ||
| Q2 25 | — | 98.7% | ||
| Q1 25 | — | 94.3% | ||
| Q4 24 | — | 96.6% | ||
| Q3 24 | — | 97.4% | ||
| Q2 24 | — | 96.2% | ||
| Q1 24 | — | 96.4% |
| Q4 25 | — | -25.0% | ||
| Q3 25 | -5.2% | 15.1% | ||
| Q2 25 | -5.2% | -11.1% | ||
| Q1 25 | — | -52.2% | ||
| Q4 24 | -3.9% | -81.2% | ||
| Q3 24 | -9.0% | -89.3% | ||
| Q2 24 | -3.4% | -125.1% | ||
| Q1 24 | -3.7% | -336.5% |
| Q4 25 | — | — | ||
| Q3 25 | -7.5% | 15.6% | ||
| Q2 25 | -7.3% | -11.1% | ||
| Q1 25 | — | -50.4% | ||
| Q4 24 | -5.5% | — | ||
| Q3 24 | -10.7% | -87.1% | ||
| Q2 24 | -5.1% | -130.1% | ||
| Q1 24 | -4.9% | -328.9% |
| Q4 25 | — | $0.04 | ||
| Q3 25 | $-0.20 | $0.28 | ||
| Q2 25 | $-0.20 | $-0.14 | ||
| Q1 25 | — | $-0.47 | ||
| Q4 24 | $-0.15 | $-0.71 | ||
| Q3 24 | $-0.30 | $-0.70 | ||
| Q2 24 | $-0.14 | $-0.91 | ||
| Q1 24 | $-1.64 | $-1.76 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $4.7M | $93.0M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $-38.9M | $114.8M |
| Total Assets | $280.6M | $605.2M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $93.0M | ||
| Q3 25 | $4.7M | $110.9M | ||
| Q2 25 | $1.4M | $75.2M | ||
| Q1 25 | — | $61.9M | ||
| Q4 24 | $3.3M | $58.5M | ||
| Q3 24 | $1.8M | $36.4M | ||
| Q2 24 | $1.3M | $32.3M | ||
| Q1 24 | $3.0M | $43.3M |
| Q4 25 | — | $114.8M | ||
| Q3 25 | $-38.9M | $73.6M | ||
| Q2 25 | $-13.9M | $32.7M | ||
| Q1 25 | — | $32.8M | ||
| Q4 24 | $3.7M | $59.1M | ||
| Q3 24 | $9.6M | $-30.5M | ||
| Q2 24 | $21.9M | $15.1M | ||
| Q1 24 | $27.2M | $74.1M |
| Q4 25 | — | $605.2M | ||
| Q3 25 | $280.6M | $538.6M | ||
| Q2 25 | $319.4M | $555.3M | ||
| Q1 25 | — | $548.8M | ||
| Q4 24 | $340.5M | $594.1M | ||
| Q3 24 | $346.3M | $504.4M | ||
| Q2 24 | $360.4M | $551.1M | ||
| Q1 24 | $368.1M | $663.5M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $4.3M | $60.7M |
| Free Cash FlowOCF − Capex | $-2.8M | — |
| FCF MarginFCF / Revenue | -2.3% | — |
| Capex IntensityCapex / Revenue | 5.8% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-7.5M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $60.7M | ||
| Q3 25 | $4.3M | $14.3M | ||
| Q2 25 | $4.0M | $5.0M | ||
| Q1 25 | — | $-42.2M | ||
| Q4 24 | $5.8M | $-35.7M | ||
| Q3 24 | $4.7M | $-42.5M | ||
| Q2 24 | $7.0M | $-40.2M | ||
| Q1 24 | $164.0K | $-119.0M |
| Q4 25 | — | — | ||
| Q3 25 | $-2.8M | $14.2M | ||
| Q2 25 | $1.1M | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $-1.3M | — | ||
| Q3 24 | $-4.5M | — | ||
| Q2 24 | $-1.6M | $-40.3M | ||
| Q1 24 | $-15.2M | — |
| Q4 25 | — | — | ||
| Q3 25 | -2.3% | 8.6% | ||
| Q2 25 | 0.9% | — | ||
| Q1 25 | — | — | ||
| Q4 24 | -1.1% | — | ||
| Q3 24 | -3.5% | — | ||
| Q2 24 | -1.4% | -74.5% | ||
| Q1 24 | -12.2% | — |
| Q4 25 | — | — | ||
| Q3 25 | 5.8% | 0.1% | ||
| Q2 25 | 2.4% | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 5.8% | — | ||
| Q3 24 | 7.2% | 0.0% | ||
| Q2 24 | 7.1% | 0.2% | ||
| Q1 24 | 12.3% | 0.0% |
| Q4 25 | — | — | ||
| Q3 25 | — | 0.56× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
NDLS
| Food And Beverage | $119.6M | 98% |
| Franchise | $2.5M | 2% |
TVTX
| FILSPARI | $103.3M | 80% |
| Tiopronin Products | $23.3M | 18% |
| License | $3.1M | 2% |
